CN103275210B - Chromatographic purification method of fatty acid mono-acylation insulin - Google Patents
Chromatographic purification method of fatty acid mono-acylation insulin Download PDFInfo
- Publication number
- CN103275210B CN103275210B CN201310256421.6A CN201310256421A CN103275210B CN 103275210 B CN103275210 B CN 103275210B CN 201310256421 A CN201310256421 A CN 201310256421A CN 103275210 B CN103275210 B CN 103275210B
- Authority
- CN
- China
- Prior art keywords
- chromatographic
- insulin
- purification method
- phase
- lipid acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 36
- 238000011097 chromatography purification Methods 0.000 title claims abstract description 14
- 102000004877 Insulin Human genes 0.000 title abstract description 21
- 108090001061 Insulin Proteins 0.000 title abstract description 21
- 229940125396 insulin Drugs 0.000 title abstract description 7
- 238000005917 acylation reaction Methods 0.000 title abstract description 5
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract description 5
- 239000000194 fatty acid Substances 0.000 title abstract description 5
- 229930195729 fatty acid Natural products 0.000 title abstract description 5
- 150000004665 fatty acids Chemical class 0.000 title abstract description 5
- 239000000463 material Substances 0.000 claims abstract description 21
- 229920000620 organic polymer Polymers 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003960 organic solvent Substances 0.000 claims abstract description 8
- 230000005526 G1 to G0 transition Effects 0.000 claims abstract description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 14
- 150000002632 lipids Chemical class 0.000 claims description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 11
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 claims description 10
- 229950004152 insulin human Drugs 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 150000003016 phosphoric acids Chemical class 0.000 claims description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 claims 1
- 238000010828 elution Methods 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000012071 phase Substances 0.000 description 33
- 238000004007 reversed phase HPLC Methods 0.000 description 31
- 238000000746 purification Methods 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 11
- 239000000945 filler Substances 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000004793 Polystyrene Substances 0.000 description 8
- 229920002223 polystyrene Polymers 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000007791 liquid phase Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 108010076181 Proinsulin Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 229920000193 polymethacrylate Polymers 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- -1 carboxylic acid halides Chemical class 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000010829 isocratic elution Methods 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000004237 preparative chromatography Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229960003948 insulin detemir Drugs 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229940119528 pork insulin Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Abstract
The invention discloses a chromatographic purification method of fatty acid mono-acylation insulin. The chromatographic purification method comprises the steps of separating the fatty acid mono-acylation insulin by employing a medium- and low-pressure chromatographic system, and using an organic polymer reversion phase chromatographic material as a stationary phase, and taking at least one organic solvent mixable with water and at least one buffering agent substance as an elution moving phase with the pH (Potential of Hydrogen) value of 2-4. The chromatographic purification method has simple steps, is easy to amplify, and low in economic cost, and can increase the purity of a sample from original 50-60% to 98% by one step.
Description
Technical field
The present invention relates to a kind of chromatographic purification method, particularly a kind of chromatographic purification method of lipid acid list acylated insulin.
Background technology
Aminoacylates is common protein modified method, and the universal method of acidylate is common in " Enzymology method " published by Elsevier of C.H.W.Hirs chief editor, 25:494-499(1972).
Namely the insulin detemir that Novo Nordisk Co., Ltd of current Denmark produces is the common insulin derivates utilizing this principle to obtain after the epsilon-amino acidylate of B29 position Lys residue is modified.And in the aminoacylation of Regular Insulin; generally use active ester, carboxylic acid halides or acid anhydrides in the industry at present; react with proinsulin or analogue and prepare single acylated insulin; but due in proinsulin or analogue containing the free epsilon-amino (epsilon-amino of such as Lys) be positioned on the amino acid whose free alpha-amino group of A1, B1 position and other amino acid side chains; these three kinds of free amine groups all can form covalent bonds with active ester, carboxylic acid halides or acid anhydrides, thus define the monosubstituted Regular Insulin of above common different loci modification or two replacement insulin protein product.Therefore, how selective modification Regular Insulin and subsequent purification thereof just important problem can be become preferably.At biology magazine Biochem.J121:737-745(1971) Lindsay etc. provides the experimental data of Regular Insulin and the reaction of acetic acid N-succinimide ester in The acylation of insulin mono-literary composition published, mainly generates Phe
b1the monosubstituted Regular Insulin of-ethanoyl, Gly
a1the monosubstituted Regular Insulin of-ethanoyl, Lys
b29-monosubstituted ethanoyl Regular Insulin and a small amount of two replacement Regular Insulin, it adopts DEAE ion-exchange packing to study purifying research of product afterwards.Find use the method to have certain purification effect but be also not so good as people's will, although because the display of purity result can reach more than 90% on its document, but due on purity result decision method, Lindsay the electric gel electrophoresis method such as to be only the use of as detection method, and the method is compared with HPLC method conventional in current industry, sensitivity is low.At protein & peptide letters, Synthesis 13:135-142(2006) published, in Characterization and Biological Activity of Chemically Modified Insulin DerivativeWith Alpha Lipoic Acid mono-literary composition, Tao Huang etc. adopt lipoylbenzotriazole and insulin human to react in the basic conditions, generate with ε-Lys
b29-lipoyl-insulin is main single acidylate modified outcome.Afterwards, the RP-HPLC that it has mainly used with C18 reverse phase silica gel is stationary phase carries out purifying, obtain purity higher than 95% single acylated insulin.Chinese patent CN1171742 provides the method for the epsilon-amino of a kind of selective reaction acidylate modified human proinsulin and analogue thereof; in the disclosure in this patent; which employs with C4 reverse phase silica gel be stationary phase RP-HPLC or semipreparative column; moving phase is the method for carrying out gradient elution containing the solvent systems of 0.1%TFA, acetonitrile and water, and when 53% acetonitrile concentration, obtain single acylated insulin (purity data does not disclose).
As can be seen here, the Regular Insulin after modifying for acidylate is at present more adopt RP-HPLC or high pressure to prepare liquid phase to carry out liquid phase separation purifying on reverse phase silica gel solid substrate.Term RP-HPLC refers to the method adopting anti-phase stationary phase separation and purification on high performance liquid phase instrument, and high pressure is prepared liquid phase and referred under high pressure the liquid chromatography that (the general pressure that uses is at 5-15Mpa) runs.Reverse phase silica gel is then interpreted as hydrophobic matrix and has applied superincumbent silica material, wherein the alkane of hydrophobic matrix example to be chain length be C3-C20, particularly C4-C18.
Although employing is prepared in liquid phase at HPLC or high pressure can reach higher separation purity with reverse phase silica gel material as stationary phase, the method has some obvious shortcomings.Such as reverse phase silica gel is only stable within the scope of pH2-10; and easily produce a large amount of hydrophobicity very strong impurity during fatty-acylation modification Regular Insulin; the dimer of such as free fatty acids or fatty acid modifying or polymer; it is very firm that they easily adsorb on silica gel; and neither easily by the regenerative elution of routine; along with the prolongation of time, impurity is easily concentrated on filler.Alkali washing method can only be adopted to clean, but alkali lye easily destroy the chemical property of reverse phase silica gel and then affect the separating effect of filler.Meanwhile, if adopt RP-HPLC or high pressure half preparation liquid phase instrument as separation and purification instrument, although it has accurately feature efficiently, its cost high maintenance bothers, and especially cost at least exceeds 50% than mesolow chromatographic system.
Summary of the invention
For overcoming above-mentioned shortcoming and defect, the object of the present invention is to provide with a kind of chromatographic purification method of lipid acid list acylated insulin.This purification process uses a kind of than the more convenient use of reverse phase silica gel, cheap chromatographic material, and chromatogram purification acidylate modifies Regular Insulin thereon.Use this method can reach use one step chromatogram purification and can obtain highly purified acidylate modification Regular Insulin.
Object of the present invention is achieved through the following technical solutions: a kind of chromatographic purification method of lipid acid list acylated insulin, comprise following steps: utilize mesolow chromatographic system to be separated lipid acid list acylated insulin, use organic polymer reversion phase chromatographic material to be stationary phase, the moving phase of wash-out is can the organic solvent miscible with water and at least one buffer material, pH value be 2 ~ 4 containing at least one;
Described lipid acid list acylated insulin refers to the naturally occurring longer chain fatty acid or its analogue that are connected to side chain at the alpha-amino group place of parent insu B chain-terminal amino acid residue or the epsilon-amino place of Lys residue that exists on B chain, and this side chain has following general general formula:
-X-Y；
Wherein X be and parent insu B chain-terminal amino acid residue alpha-amino group or and the epsilon-amino of parent insu B chain Lys residue between covalent linkage;
X is :-CO-;
Y is :-(CH
2) m-, wherein m is the integer of 6 ~ 32;
And wherein parent insu is selected from insulin human, des(B1) insulin human, des(B30) insulin human, Gly
a21insulin human, Gly
a21des(B30) insulin human, Asp
b28insulin human, pork insulin, Lys
b28pro
b29insulin human, Gly
a21arg
b31arg
b32insulin human or Lys
b3glu
b29insulin human.
Described lipid acid list acylated insulin is preferably (N
ε B29-myristoyl) Lys
b29des(B30) insulin human, (N
ε B29-myristoyl) Lys
b29insulin human or (N
ε B29-hexadecanoyl) Lys
b29des(B30) insulin human; Be more preferably (N
ε B29-myristoyl) Lys
b29des(B30) insulin human;
Described mesolow chromatographic system refer to operating pressure be 2 ~ 25bar(bar) chromatographic system; Being preferably operating pressure is the chromatographic system of 2 ~ 20bar, is more preferably the chromatographic system that operating pressure is 5 ~ 10bar, most preferably is the chromatographic system that operating pressure is 5 ~ 8bar; Chromatographic system comprises analytical chromatographic, half preparing chromatography system, preparing chromatography system;
Described organic polymer reversion phase chromatographic material is the material for reversed phase chromatography separation purifying that polymethacrylate (PMA) or polystyrene (PS)-Vinylstyrene (DVB) are matrix, is preferably polystyrene (PS)-Vinylstyrene (DVB) material; Its mean particle size preferably 5 ~ 300 μm, is more preferably 10 ~ 50 μm; Granularity is less, and resolution is better, but the more short grained pressure stability of granularity is lower;
Described organic polymer reversion phase chromatographic material can select commercially available organic polymer reversion phase chromatographic material as shown in table 1:
Table 1
| Manufacturers | Trade(brand)name | Material | Minimum particle size | Aperture |
| Mitsubishi Chemical | MCI GEL CHP | PS/DVB、PMA | 4μm | 10nm |
| GE | Source15、30 | PS/DVB | 5μm | 10nm |
| AMBERCHROM | CG161、CG300、CG1000 | PS/DVB | 35μm | 15nm |
| Receive micro- | UniPS | PS/DVB | 3μm | 10nm |
Described organic polymer reversion phase chromatographic material is more preferably receives micro-Uni PS30-300 filler or GEsource30 filler;
Described wash-out can isocratic elution, and namely wherein have constant buffer substance concentration and constant organic solvent ratio, or can carry out by linear gradient elution, namely organic solvent ratio increases progressively in time, preferred isocratic elution;
Described organic solvent that can be miscible with water is preferably the alcohol that acetonitrile, ketone or carbonatoms are C1 ~ C4; Be preferably acetonitrile, Virahol or ethanol;
The described volumetric concentration of organic solvent in moving phase that can be miscible with water is 1 ~ 90%, is preferably 30 ~ 60%;
Described buffer material can be selected from phosphoric acid salt, acetate or Citrate trianion, is preferably SODIUM PHOSPHATE, MONOBASIC or sodium-acetate;
Described pH value can regulate by adding acetic acid, phosphoric acid, hydrochloric acid or sodium hydroxide;
Described pH value is preferably 3.0 ~ 3.5.
The present invention relative to the advantage of prior art and effect is:
1, operation steps is succinct: purification process of the present invention uses a kind of than the more convenient use of reverse phase silica gel, cheap organic polymer reversion phase chromatographic material, and chromatogram purification acidylate modifies Regular Insulin thereon.Use this method can reach use one step chromatogram purification can obtain high purity (purity reaches 98%-98.5%) acidylate modify Regular Insulin.
2, the purity requirement of purifying initial sample is low: the initial purity of sample is 50 ~ 60% can apply purification process of the present invention and carry out purifying, and the purity of the sample after purifying can reach 98%.
3, mesolow chromatographic system is adopted: adopt another benefit of the present invention to be that it can run in mesolow chromatographic system, and reasonable separation and purification effect can be obtained.
4, method of the present invention is applicable to various chromatographic system, analyzes chromatogram, half preparative chromatography, preparative chromatography, especially mesolow chromatogram.Use the method to carry out separation and purification, good cost advantage can be had.
In a word, purification process step provided by the invention is simple, a step sample purity can be brought up to 98% from 50 ~ 60%, and is easy to amplify, and Financial cost is low.
Accompanying drawing explanation
Fig. 1 is the RP-HPLC figure of the component 1 obtained when pH value is 4.0 in embodiment 1.
Fig. 2 is the RP-HPLC figure of the component 2 obtained when pH value is 4.0 in embodiment 1.
Fig. 3 is the RP-HPLC figure of the component 3 obtained when pH value is 4.0 in embodiment 1.
Fig. 4 is the RP-HPLC figure of the component 4 obtained when pH value is 4.0 in embodiment 1.
Fig. 5 is the RP-HPLC figure of the component 1 obtained when pH value is 4.3 in embodiment 1.
Fig. 6 is the RP-HPLC figure of the component 2 obtained when pH value is 4.3 in embodiment 1.
Fig. 7 is the RP-HPLC figure of the component 3 obtained when pH value is 4.3 in embodiment 1.
Fig. 8 is the RP-HPLC figure of the component 4 obtained when pH value is 4.3 in embodiment 1.
Fig. 9 is the RP-HPLC figure of the component 1 obtained when pH value is 7.0 in embodiment 1.
Figure 10 is the RP-HPLC figure of the component 2 obtained when pH value is 7.0 in embodiment 1.
Figure 11 is the RP-HPLC figure of the component 3 obtained when pH value is 7.0 in embodiment 1.
Figure 12 is the RP-HPLC figure of the component 4 obtained when pH value is 7.0 in embodiment 1.
Figure 13 is the RP-HPLC figure of the highest component of purity obtained when operating pressure is 2bar in embodiment 2.
Figure 14 is the RP-HPLC figure of the qualified component mixing obtained when operating pressure is 5bar in embodiment 2.
Figure 15 is the RP-HPLC figure of the qualified component mixing obtained when operating pressure is 8bar in embodiment 2.
Figure 16 is the RP-HPLC figure of the sample to be purified in embodiment 3.
Figure 17 is the RP-HPLC figure of the component 1 in embodiment 3.
Figure 18 is the RP-HPLC figure of the component 2 in embodiment 3.
Figure 19 is the RP-HPLC figure of the component 3 in embodiment 3.
Figure 20 is the RP-HPLC figure of the component 4 in embodiment 3.
Embodiment
Below in conjunction with embodiment and accompanying drawing, the present invention is described in further detail, but embodiments of the present invention are not limited thereto.
Embodiment 1:
(1) preparation of sample to be purified:
With reference to the embodiment 7 disclosed in patent WO98/02460,0.50g Des B30 proinsulin human is dissolved in 7.0ml dimethyl sulfoxide (DMSO) (DMSO) with the mixing solutions of 3.5ml water, and regulate pH to be 10.2-10.5 toward wherein adding 0.4ml triethylamine, obtain mixing solutions.Afterwards 0.025g N-succinimido myristic acid is dissolved in 1.8ml N-Methyl pyrrolidone solution; and be added dropwise in aforementioned mixing solutions; stir reaction in 2 hours under finally the solution mixed being placed in 0 DEG C of environment, the insulin derivates modified containing acidylate can be obtained, i.e. (N
ε B29-myristoyl) Lys
b29des(B30) reaction solution of insulin human.Sample to be purified is obtained afterwards with its acidifying being diluted 10 times containing vinegar aqueous acid (concentration of acetic acid is volume percent 10%).The purity of this sample to be purified as shown in figure 16.
(2) QuickSep medium pressure chromatography system purifying is used:
The chromatography column of diameter 16mm and long 250mm is tested, in chromatography column load filler be 30ml receive micro-Uni PS30-300 filler (particle diameter 30 μm, aperture 300 dust), bed height is 150mm.Loading target protein amount is 100mg.
Chromatography buffer is: A phase, the 0.1M phosphate sodium dihydrogen buffer solution containing 50mM anhydrous sodium sulphate, regulates phosphoric acid or Sodium phosphate dibasic ratio in damping fluid, makes it pH value and be respectively 4.0,4.3 and 7.0; B phase, aqueous isopropanol.Pillar is first with 30%B(and B phase and the 3:7 mixing by volume of A phase) balance each other, regulate loading sample elution to adopt 38%B equality wash-out, elution flow rate 70ml/h, operating pressure 5bar, 280nmUV detector monitors out Fractional Collections behind peak, every section of 10ml.
(3) method for detecting purity:
Adopt RP-HPLC method detecting step (2) to collect component, instrument is Shimadzu LC-2010CHT, and pillar adopts Sepax GP-C4 reversed-phase column.With ammoniumsulphate soln (ammonium sulfate 40g, the 1900ml that adds water dissolve after, with 1mol/L sulfuric acid adjust pH to 2.3, add water to 2000ml): acetonitrile by volume the mixing solutions that obtains of 1800:200 as mobile phase A; With acetonitrile-water (800:225 mixing by volume), for Mobile phase B, flow velocity is 1.0ml/min; Column temperature is 50 DEG C, determined wavelength 214nm.30 ~ 68%B phase gradient wash-out 75min.Retention time 30 ~ 31min unimodal namely for the purpose of product.Purity calculates and adopts area normalization method.
Fig. 1 ~ 12 are the RP-HPLC collection of illustrative plates of each component.
List in table 2 and use polymer materials to receive the purity of micro-Uni PS30-300 each collection component of Virahol wash-out under different pH, can find out, the collection component that purity is greater than 98.0% can be obtained when pH4.0, then can not obtain at pH4.3 and pH7.0 the component that purity is greater than 98.0%.
Table 2
Embodiment 2:
(1) preparation of sample to be purified: with step (1) in embodiment 1.
(2) QuickSep medium pressure chromatography system purifying is used:
That in the chromatography column of diameter 11mm and long 250mm, loads 10ml receives micro-Uni PS30-300 filler (particle diameter 30 μm, aperture 300 dust), bed height 110mm.
Moving phase configuration proportion is with embodiment 1, and the pH regulating mobile phase A is 3.0.Regulate loading sample size, make filler target protein lifting capacity in pillar be 4.0g/L.Regulating course analysis system operating pressure, makes it to be respectively 2bar, 5bar and 8bar.Type of elution is with embodiment 1.280nm UV detector monitors out Fractional Collections behind peak, every section of 10ml, then after component mixing purity being greater than 98.0%, then detects purity and concentration, calculate the rate of recovery.
(3) method for detecting purity: with step (3) in embodiment 1.
Figure 13 is the RP-HPLC collection of illustrative plates of the highest purity using Uni PS30-300 polymer materials wash-out under 2bar pressure condition.
Figure 14 ~ 15 are for using Uni PS30-300 polymer materials mixed RP-HPLC collection of illustrative plates of the qualified component of wash-out under 5bar and 8bar pressure condition.
List experimental result in table 3, be analyzed as follows: under different chromatographic system operating pressure conditions, the purity of more than 98.0% can be reached under 5bar and 8bar pressure condition, and productive rate can reach more than 70%.And under the operating pressure of 2bar, the highest purity of component can only reach 96.24%, therefore its yield is 0.
Table 3
Embodiment 3:
(1) preparation of sample to be purified: with step (1) in embodiment 1.
(2) QuickSep medium pressure chromatography system purifying is used:
The GE source30 filler (particle diameter 30 μm) of 2.5L is loaded, the long 165mm of bed in the chromatography column of diameter 140mm and long 500mm.
Chromatography buffer is: A phase, 0.15M sodium-acetate buffer, pH3.0; B phase, containing TFA(trifluoroacetic acid) acetonitrile solution, the concentration of TFA is volume percent 0.1%.
Pillar first balances each other with 10%B, i.e. A phase and B phase 9:1 mixing by volume, after balance, loading makes filler target protein lifting capacity be 4.0g/L, 40%B equality wash-out, elution speed 5.7L/h, operating pressure is that 8bar, 280nmUV detector monitors out Fractional Collections behind peak, every section of 1.0L volume.
(3) method for detecting purity: with step (3) in embodiment 1.
Figure 16 is the RP-HPLC collection of illustrative plates of the sample to be purified before loading, and its purity area is 58.31%.
Figure 17 ~ 20 are the RP-HPLC collection of illustrative plates of each collection component.
The result listing each collection component in table 4 can be clear that, use the method also can have good separation and purification effect at the GE source30 polymer packing of 2.5L scale, and purity can bring up to 98% from 58.31% of sample to be purified, the component being greater than 98% with purity is qualified, then yield reaches 71.90%.
Table 4
Above-described embodiment is the present invention's preferably embodiment; but embodiments of the present invention are not restricted to the described embodiments; change, the modification done under other any does not deviate from spirit of the present invention and principle, substitute, combine, simplify; all should be the substitute mode of equivalence, be included within protection scope of the present invention.
Claims (5)
1. the chromatographic purification method of a lipid acid list acylated insulin, it is characterized in that comprising following steps: utilize mesolow chromatographic system to be separated lipid acid list acylated insulin, use organic polymer reversion phase chromatographic material to be stationary phase, the moving phase of wash-out is can the organic solvent miscible with water and at least one buffer material, pH value be 2 ~ 4 containing at least one;
Described lipid acid list acylated insulin is Methionin B29 (N
ε-mnyristoyl) go (B30) insulin human;
Described organic polymer reversion phase chromatographic material is polystyrene-divinylbenzene;
Described can the alcohol of the organic solvent miscible with water to be acetonitrile, ketone or carbonatoms be C1 ~ C4;
Described buffer material is phosphoric acid salt, acetate or Citrate trianion.
2. the chromatographic purification method of lipid acid list acylated insulin according to claim 1, is characterized in that: the chromatographic system of described mesolow chromatographic system to be operating pressure be 2 ~ 25 bar.
3. the chromatographic purification method of lipid acid list acylated insulin according to claim 1, is characterized in that: the mean particle size of described organic polymer reversion phase chromatographic material is 5 ~ 300 μm.
4. the chromatographic purification method of lipid acid list acylated insulin according to claim 3, is characterized in that: described organic polymer reversion phase chromatographic material is one in MCI GEL CHP, Source15, Source30, CG161, CG300, CG1000 and Uni PS or at least two kinds.
5. the chromatographic purification method of lipid acid list acylated insulin according to claim 1, is characterized in that: described pH value is 3.0 ~ 3.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310256421.6A CN103275210B (en) | 2013-06-25 | 2013-06-25 | Chromatographic purification method of fatty acid mono-acylation insulin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310256421.6A CN103275210B (en) | 2013-06-25 | 2013-06-25 | Chromatographic purification method of fatty acid mono-acylation insulin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103275210A CN103275210A (en) | 2013-09-04 |
| CN103275210B true CN103275210B (en) | 2015-02-25 |
Family
ID=49057851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310256421.6A Active CN103275210B (en) | 2013-06-25 | 2013-06-25 | Chromatographic purification method of fatty acid mono-acylation insulin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103275210B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103467593B (en) * | 2013-09-05 | 2015-05-13 | 杭州阿德莱诺泰制药技术有限公司 | Purification method of thymalfasin |
| CN105658325A (en) * | 2013-10-10 | 2016-06-08 | 通用电气医疗集团生物工艺研发股份公司 | Method for production of a chromatography material |
| CN109748948B (en) * | 2018-11-27 | 2020-04-21 | 珠海冀百康生物科技有限公司 | Purification method of palmitoyl tetrapeptide-7 |
| CN111518193B (en) * | 2020-06-11 | 2023-09-26 | 南京赛诺生物制药有限公司 | Purification method of fatty acid acylated insulin and GLP-1 polypeptide |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1313866A (en) * | 1998-08-24 | 2001-09-19 | 阿文蒂斯药物德国有限公司 | Method for chromatographically purifying insulins |
-
2013
- 2013-06-25 CN CN201310256421.6A patent/CN103275210B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1313866A (en) * | 1998-08-24 | 2001-09-19 | 阿文蒂斯药物德国有限公司 | Method for chromatographically purifying insulins |
Non-Patent Citations (1)
| Title |
|---|
| 邵承伟.高聚物型液相色谱柱在蛋白分离中的应用研究.《分析试验室》.2008,第27卷(第12期),摘要,第15页左栏第1-2段. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103275210A (en) | 2013-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103275210B (en) | Chromatographic purification method of fatty acid mono-acylation insulin | |
| CN111505161A (en) | Method for detecting enantiomer of protected amino acid | |
| US11312744B2 (en) | Method for purifying long chain polypeptide | |
| RU2222546C2 (en) | Method for purification of insulin by chromatography method | |
| Schwarzer et al. | Rapid quantification of the nitrification inhibitor dicyandiamide in soil samples, nutrient media and bacterial cell-free extracts | |
| Brückner | Enantiomeric resolution of N-methyl-α-amino acids and α-alkyl-α-amino acids by ligand-exchange chromatography | |
| Jackson et al. | Composition, properties, and substrate specificities of Myxobacter AL-1 protease | |
| US20150360146A1 (en) | Purification of Organic Compounds Using Surrogate Stationary Phases on Reversed Phase Columns | |
| CN110658289B (en) | Purification method of RGD peptide containing multiple cysteines | |
| Al Musaimi et al. | Advances in therapeutic peptides separation and purification | |
| Sarvin et al. | Silica immobilised chloro-and amido-derivatives of eremomycine as chiral stationary phases for the enantioseparation of amino acids by reversed-phase liquid chromatography | |
| Lievore et al. | Benefits of a mixed-mode stationary phase to address the challenging purification of an industrially relevant peptide: a proof-of-concept study | |
| Ding et al. | Mixed-mode reversed phase/positively charged repulsion chromatography for intact protein separation | |
| Beattie et al. | Rat metallothionein‐2 contains Nα‐acetylated and unacetylated isoforms | |
| Lawless et al. | Quantitation of a 36-amino-acid peptide inhibitor of HIV-1 membrane fusion in animal and human plasma using high-performance liquid chromatography and fluorescence detection | |
| Antonsson et al. | Modification of amino groups in EF‐Tu· GTP and the ternary complex EF‐Tu· GTP· valyl‐tRNAVal | |
| CN108218954A (en) | A kind of separation method of protein | |
| Bomba et al. | Carbonyl sulfide as a prebiotic activation agent for stereo-and sequence-selective, amyloid-templated peptide elongation | |
| CN110618202B (en) | Method for detecting protein purity | |
| RUVO et al. | End‐group modified retro‐inverso isomers of tripeptide oxytocin analogues: Binding to neurophysin II and enhancement of its self‐association properties | |
| CN111044636A (en) | Analytical method of micafungin content | |
| Mohammadian-Mosaabadi et al. | Improving purification of recombinant human interferon γ expressed in Escherichia coli; effect of removal of impurity on the process yield | |
| Olson et al. | Applications of ultrafast HPLC to process development of recombinant DNA‐derived proteins | |
| Shenbagamurthi et al. | Purification of synthetic analogues of yeast mating hormone by reversed-phase chromatography | |
| US11198718B2 (en) | Purifying insulin using cation exchange and reverse phase chromatography in the presence of an organic modifier and elevated temperature |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |